欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Orencia
适用类别Human
治疗领域Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid
通用名/非专利名称abatacept
活性成分abatacept
产品号EMEA/H/C/000701
患者安全信息No
许可状态Authorised
ATC编码L04AA24
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2007/05/21
上市许可开发者/申请人/持有人Bristol-Myers Squibb Pharma EEIG
人用药物治疗学分组Immunosuppressants
兽用药物治疗学分组
审评意见日期2007/03/22
欧盟委员会决定日期2024/06/24
修订号41
治疗适应症Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Psoriatic arthritis Orencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.  Polyarticular juvenile idiopathic arthritis Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy. Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.
适用物种
兽用药物ATC编码
首次发布日期2017/07/25
最后更新日期2025/05/19
产品说明书https://www.ema.europa.eu/en/documents/product-information/orencia-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/orencia
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase